While the Delta variant case frequency for US infections is ~20% overall by @CDCgov, there's marked heterogeneity among states ft.com/content/730e35… by @nikasgari and @jburnmurdoch (@FT estimates Delta prevalence much higher 37-42%)
The 3 states--Missouri, Utah, Arkansas--with highest Delta variant prevalence are all increasing in cases, leading the country (still relatively low cases/capita rates), going in the opposite direction as most of the country /2
There are other states with some increase in cases where Delta is out-competing Alpha /3
And the cases is these states represent admixture of the 2 variants in different proportions /4
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Genome editing with #CRISPR is the most important life science breakthrough of our time. It's a B.C. and A.C. We interviewed @WalterIsaacson about his new book, THE CODE BREAKER, which is a masterpiece medscape.com/viewarticle/95…
w/ transcript /1
We started the conversation reading 2 key passages that convey the significance of #CRISPR /2
The Delta variant: updates from the new @PHE_Uk report assets.publishing.service.gov.uk/government/upl…
1st dose vaccine (either AZ or Pfizer) quite protective vs hospitalization
Fully vaxxed vs unvaxxed:
Infections 7.7% vs 67%
Hospitalizations 8% vs 48%
Delta's secondary attack rate is coming down some in the latest dataset. Its enhanced transmission over alpha appears to be more in the 40-60% range
Reinfections by sequencing data: 311/1260 were Delta
This 71-page report is rich. And that 60% of infections are getting sequenced (91% are Delta) is quite impressive.
It makes the output from CDC and the genomic surveillance in the US particularly weak
Just a reminder how damn lucky we are to have hit 95% efficacy of 2 mRNA vaccines, setting such an unexpectedly high bar, right from the get go, in November 2020. nytimes.com/live/2021/06/1…
Using the variants as the explanation for low @CureVacRNA efficacy doesn't work, IMO, when the known ones, with substantial immune evasion, beta and delta, are not on the list
B.1.1.7 (alpha) is a variant of concern, globally dominant. It has essentially little/no immune escape. If there's beta or delta in the VOCs that should have been stipulated. The only other 1 is gamma (P.1) w/ intermediate evasion, not shown to materially affect other vaccines
Just published @TheLancet
The #DeltaVariant experience in Scotland thelancet.com/journals/lance… 1. #VaccinesWork ("AZ appeared less effective than Pfizer") 2. Younger, unvaccinated got the delta infections 3. Doubling of hospital admissions compared with alpha (B.1.1.7) variant
Details from over 19,500 infections and 377 hospital admissions, the extraordinary prospective Scotland dataset
The doubling of hospital admissions compared with alpha doesn't mean it's more pathogenic. The 60% increase in contagiousness could do that
More @FT@mroliverbarnesft.com/content/885d9a…
Trying to figure out how @US_FDA approved the alzheimer's drug w/o adequate evidence, against their Advisory Committee, but has yet to approve full licensure for mRNA vaccines—which could save lives, prevent the toll of the delta variant, and promote durable US🦠 containment
When was the last time 350 million doses of anything were administered under an emergency authorization?
Never
Now add the extraordinary track record of safety and 95% efficacy and effectiveness.
Time to make a statement @DrWoodcockFDA
Just a reminder these were not typical Biologic Licensing Applications (BLAs). Sections were serially submitted and reviewed for months before the final applications were filed.
Full licensure is a BFD.
Nothing else would have as big and rapid an impact on US vaccinations.
With a strong vaccination campaign, the United States was able to reduce the B.1.1.7 (alpha) variant's toll to a bump in cases
What might happen with B.1.617.2 (delta) which is ~50% more transmissible, and more evasive to our immune response? /1
It will be hitting us with a far less case burden, as we approach containment for the 1st time.
But still much vulnerability d/t half the population unvaccinated and ~40% fully vaccinated
2 doses appear to be needed to get to high ~90% effectiveness /2
We'll likely see a bump in cases and adverse outcomes (magnitude uncertain) largely among unvaccinated, and a challenge to get to containment in a fully reopened country, prolonging the pandemic here /3
Graphic adapted from @tomhcalver@thetimes